Check out Comprehensive Prescribing Information OPDIVO® (nivolumab) is indicated for that treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed soon after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or just after 3 or maybe more strains of systemic therapy that featu